199 related articles for article (PubMed ID: 30236129)
1. Molecular and cellular characterizations of human cherubism: disease aggressiveness depends on osteoclast differentiation.
Kadlub N; Sessiecq Q; Mandavit M; L'Hermine AC; Badoual C; Galmiche L; Berdal A; Descroix V; Picard A; Coudert AE
Orphanet J Rare Dis; 2018 Sep; 13(1):166. PubMed ID: 30236129
[TBL] [Abstract][Full Text] [Related]
2. SH3BP2 cherubism mutation potentiates TNF-α-induced osteoclastogenesis via NFATc1 and TNF-α-mediated inflammatory bone loss.
Mukai T; Ishida S; Ishikawa R; Yoshitaka T; Kittaka M; Gallant R; Lin YL; Rottapel R; Brotto M; Reichenberger EJ; Ueki Y
J Bone Miner Res; 2014 Dec; 29(12):2618-35. PubMed ID: 24916406
[TBL] [Abstract][Full Text] [Related]
3. Defining a new aggressiveness classification and using NFATc1 localization as a prognostic factor in cherubism.
Kadlub N; Sessiecq Q; Dainese L; Joly A; Lehalle D; Marlin S; Badoual C; Galmiche L; Majoufre-Lefebvre C; Berdal A; Deckert M; Vazquez MP; Descroix V; Coudert AE; Picard A
Hum Pathol; 2016 Dec; 58():62-71. PubMed ID: 27498064
[TBL] [Abstract][Full Text] [Related]
4. Multinucleated giant cells in various forms of giant cell containing lesions of the jaws express features of osteoclasts.
Liu B; Yu SF; Li TJ
J Oral Pathol Med; 2003 Jul; 32(6):367-75. PubMed ID: 12787044
[TBL] [Abstract][Full Text] [Related]
5. NFATc1 and TNFalpha expression in giant cell lesions of the jaws.
Amaral FR; Brito JA; Perdigão PF; Carvalho VM; de Souza PE; Gomez MV; De Marco L; Gomez RS
J Oral Pathol Med; 2010 Mar; 39(3):269-74. PubMed ID: 20002873
[TBL] [Abstract][Full Text] [Related]
6. The calcineurin inhibitor tacrolimus as a new therapy in severe cherubism.
Kadlub N; Vazquez MP; Galmiche L; L'Herminé AC; Dainese L; Ulinski T; Fauroux B; Pavlov I; Badoual C; Marlin S; Deckert M; Leboulanger N; Berdal A; Descroix V; Picard A; Coudert AE
J Bone Miner Res; 2015 May; 30(5):878-85. PubMed ID: 25491283
[TBL] [Abstract][Full Text] [Related]
7. SH3BP2 is rarely mutated in exon 9 in giant cell lesions outside cherubism.
Lietman SA; Prescott NL; Hicks DG; Westra WH; Levine MA
Clin Orthop Relat Res; 2007 Jun; 459():22-7. PubMed ID: 17545756
[TBL] [Abstract][Full Text] [Related]
8. Rescue of a cherubism bone marrow stromal culture phenotype by reducing TGFβ signaling.
Liu Y; Sharma T; Chen IP; Reichenberger E; Ueki Y; Arif Y; Parisi D; Maye P
Bone; 2018 Jun; 111():28-35. PubMed ID: 29530719
[TBL] [Abstract][Full Text] [Related]
9. Jawing about TNF: new hope for cherubism.
Novack DV; Faccio R
Cell; 2007 Jan; 128(1):15-7. PubMed ID: 17218248
[TBL] [Abstract][Full Text] [Related]
10. NFATc1 in mice represses osteoprotegerin during osteoclastogenesis and dissociates systemic osteopenia from inflammation in cherubism.
Aliprantis AO; Ueki Y; Sulyanto R; Park A; Sigrist KS; Sharma SM; Ostrowski MC; Olsen BR; Glimcher LH
J Clin Invest; 2008 Nov; 118(11):3775-89. PubMed ID: 18846253
[TBL] [Abstract][Full Text] [Related]
11. Pro416Arg cherubism mutation in Sh3bp2 knock-in mice affects osteoblasts and alters bone mineral and matrix properties.
Wang CJ; Chen IP; Koczon-Jaremko B; Boskey AL; Ueki Y; Kuhn L; Reichenberger EJ
Bone; 2010 May; 46(5):1306-15. PubMed ID: 20117257
[TBL] [Abstract][Full Text] [Related]
12. Cherubism Mice Also Deficient in c-Fos Exhibit Inflammatory Bone Destruction Executed by Macrophages That Express MMP14 Despite the Absence of TRAP+ Osteoclasts.
Kittaka M; Mayahara K; Mukai T; Yoshimoto T; Yoshitaka T; Gorski JP; Ueki Y
J Bone Miner Res; 2018 Jan; 33(1):167-181. PubMed ID: 28914985
[TBL] [Abstract][Full Text] [Related]
13. Increased myeloid cell responses to M-CSF and RANKL cause bone loss and inflammation in SH3BP2 "cherubism" mice.
Ueki Y; Lin CY; Senoo M; Ebihara T; Agata N; Onji M; Saheki Y; Kawai T; Mukherjee PM; Reichenberger E; Olsen BR
Cell; 2007 Jan; 128(1):71-83. PubMed ID: 17218256
[TBL] [Abstract][Full Text] [Related]
14. Investigation of the SH3BP2 gene mutation in cherubism.
Lee JY; Jung YS; Kim SA; Lee SH; Ahn SG; Yoon JH
Acta Med Okayama; 2008 Jun; 62(3):209-12. PubMed ID: 18596838
[TBL] [Abstract][Full Text] [Related]
15. SH3BP2 gain-of-function mutation exacerbates inflammation and bone loss in a murine collagen-induced arthritis model.
Mukai T; Gallant R; Ishida S; Yoshitaka T; Kittaka M; Nishida K; Fox DA; Morita Y; Ueki Y
PLoS One; 2014; 9(8):e105518. PubMed ID: 25144740
[TBL] [Abstract][Full Text] [Related]
16. RANK-Independent Osteoclast Formation and Bone Erosion in Inflammatory Arthritis.
O'Brien W; Fissel BM; Maeda Y; Yan J; Ge X; Gravallese EM; Aliprantis AO; Charles JF
Arthritis Rheumatol; 2016 Dec; 68(12):2889-2900. PubMed ID: 27563728
[TBL] [Abstract][Full Text] [Related]
17. CTRP3 acts as a negative regulator of osteoclastogenesis through AMPK-c-Fos-NFATc1 signaling in vitro and RANKL-induced calvarial bone destruction in vivo.
Kim JY; Min JY; Baek JM; Ahn SJ; Jun HY; Yoon KH; Choi MK; Lee MS; Oh J
Bone; 2015 Oct; 79():242-51. PubMed ID: 26103094
[TBL] [Abstract][Full Text] [Related]
18. [Molecular and Cellular Pathogenesis of Cherubism].
Ueki Y
Clin Calcium; 2016 Jun; 26(6):918-26. PubMed ID: 27230848
[TBL] [Abstract][Full Text] [Related]
19. RGS18 acts as a negative regulator of osteoclastogenesis by modulating the acid-sensing OGR1/NFAT signaling pathway.
Iwai K; Koike M; Ohshima S; Miyatake K; Uchiyama Y; Saeki Y; Ishii M
J Bone Miner Res; 2007 Oct; 22(10):1612-20. PubMed ID: 17576169
[TBL] [Abstract][Full Text] [Related]
20. SH3BP2 is an activator of NFAT activity and osteoclastogenesis.
Lietman SA; Yin L; Levine MA
Biochem Biophys Res Commun; 2008 Jul; 371(4):644-8. PubMed ID: 18440306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]